Antisoma

Cancer drug developer sums up pipeline progress

Published in Oncology Business Week, January 29th, 2006

Cancer drug developer Antisoma plc (ASM; ATSMY) held its annual general meeting recently where CEO Glyn Edwards reviewed the company's progress since its preliminary year-end results:

"Since September we have announced preliminary phase II data on AS1404, reported additional clinical findings on AS1411 and strengthened our balance sheet through a GBP6.55 million share placing," noted Edwards.

Of the company's clinical pipeline developments, Edwards said:

"In October we announced promising preliminary findings from our phase II study of AS1404 in lung cancer. At that time, initial data were available from 47 patients, of whom 23...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2006-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry